Cause-specific mortality associated with HIV and HTLV-II infections among injecting drug users in the USA

被引:36
作者
Goedert, JI
Fung, MM
Felton, S
Battjes, RJ
Engels, EA
机构
[1] NCI, Viral Epidemiol Branch, Rockville, MD USA
[2] Res Triangle Inst, Washington, DC USA
[3] Friends Res Inst, Baltimore, MD USA
[4] NIDA, Rockville, MD USA
关键词
HIV infection; HTLV-II infection; injecting drug use; mortality; overdose; tuberculosis; pneumonia; cancer;
D O I
10.1097/00002030-200107060-00012
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: Human T-lymphotropic virus type II (HTLV-II) is widespread among injecting drug users (IDU) and may contribute to the risk of leukemia/lymphoma, neurodegenerative disease, and perhaps pneumonia, especially with HIV co-infection. Methods: In 1987-1991, 6570 IDU were tested for HIV and HTLV-II antibodies. In 1998, they were matched to the National Death Index. Numbers of observed deaths of each cause were compared by standardized mortality ratios with the numbers expected, using sex-, race-, age-, and year-specific rates in the general population. Relative risk (RR) associated with each virus, compared to uninfected drug users, was estimated by Poisson modeling. Results: There were 1351 deaths, including 683 (15%) of 4604 participants who enrolled seronegative for both viruses; 328 (47%) of 701 who had HIV but not HTLV-II infection; 220 (21%) of 1033 who had HTLV-II but not HIV infection; and 120 (52%) of 232 who were infected by both viruses. Compared to the general population, mortality for participants with neither virus was increased 4.3-fold [95% confidence interval (CI), 4.0-4.7] and was significantly elevated for virtually every cause of death. With HIV, mortality from medical causes, but not external causes, was increased 3.7-fold (95% CI, 3.3-4.2), particularly with AIDS and related conditions. With HTLV-II, all-cause mortality was reduced (RR, 0.8; 95% CI, 0.7-0.9), with no statistically significant reduction or elevation for any specific cause. A non-significant excess of tuberculosis deaths (RR 4.6; 95% CI, 0.8-25.2) was noted with HTLV-II, but there was no excess mortality from leukemia/lymphoma, other malignancies, or neurodegenerative disease. Conclusions: Without HIV or HTLV-II, IDU had profoundly increased mortality from medical and external causes. HIV was specifically associated with death due to AIDS and related conditions. HTLV-II infection was not significantly associated with mortality from any cause, suggesting that it is not a significant human pathogen, even when present with HIV infection. (C) 2001 Lippincott Williams & Wilkins.
引用
收藏
页码:1295 / 1302
页数:8
相关论文
共 34 条
[1]  
Andersen R, 2000, HEALTH SERV RES, V35, P389
[2]   Genetic variants of human T-lymphotropic virus type II in American Indian groups [J].
Biggar, RJ ;
Taylor, ME ;
Neel, JV ;
Hjelle, B ;
Levine, PH ;
Black, FL ;
Shaw, GM ;
Sharp, PM ;
Hahn, BH .
VIROLOGY, 1996, 216 (01) :165-173
[3]   ENDEMIC TRANSMISSION OF HTLV TYPE-II AMONG KAYAPO INDIANS OF BRAZIL [J].
BLACK, FL ;
BIGGAR, RJ ;
NEEL, JV ;
MALONEY, EM ;
WATERS, DJ .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 1994, 10 (09) :1165-1171
[4]   Twenty-five years of HTLV type II follow-up with a possible case of tropical spastic paraparesis in the Kayapo, a Brazilian Indian tribe [J].
Black, FL ;
Biggar, RJ ;
Lal, RB ;
Gabbai, AA ;
Vieira, JPB .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 1996, 12 (17) :1623-1627
[5]   SEROPREVALENCE OF HUMAN T-CELL LYMPHOTROPIC VIRUS TYPE-II INFECTION, WITH OR WITHOUT HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 COINFECTION, AMONG US INTRAVENOUS-DRUG-USERS [J].
BRIGGS, NC ;
BATTJES, RJ ;
CANTOR, KP ;
BLATTNER, WA ;
YELLIN, FM ;
WILSON, S ;
RITZ, AL ;
WEISS, SH ;
GOEDERT, JJ .
JOURNAL OF INFECTIOUS DISEASES, 1995, 172 (01) :51-58
[6]  
CANTOR KP, 1991, J ACQ IMMUN DEF SYND, V4, P460
[7]   Identification and characterization of a new and distinct molecular subtype of human T-Cell lymphotropic virus type 2 [J].
Eiraku, N ;
Novoa, P ;
Ferreira, MD ;
Monken, C ;
Ishak, R ;
Ferreira, OD ;
Zhu, SW ;
Lorenco, R ;
Ishak, M ;
Azvedo, V ;
Guerreiro, J ;
deOliveira, MP ;
Loureiro, P ;
Hammerschlak, N ;
Ijichi, S ;
Hall, WW .
JOURNAL OF VIROLOGY, 1996, 70 (03) :1481-1492
[8]   Mortality among drug users in the AIDS era [J].
Goedert, JJ ;
Pizza, G ;
Gritti, FM ;
Costigiola, P ;
Boschini, A ;
Bini, A ;
Lazzari, C ;
Palareti, A .
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, 1995, 24 (06) :1204-1210
[9]   Human T lymphotropic virus type II (HTLV-II): Epidemiology, molecular properties, and clinical features of infection [J].
Hall, WW ;
Ishak, R ;
Zhu, SW ;
Novoa, P ;
Eiraku, N ;
Takahashi, H ;
Ferreira, MD ;
Azevedo, V ;
Ishak, MOG ;
Ferreira, OD ;
Monken, C ;
Kurata, T .
JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 1996, 13 :S204-S214
[10]   CHRONIC NEURODEGENERATIVE DISEASE ASSOCIATED WITH HTLV-II INFECTION [J].
HJELLE, B ;
APPENZELLER, O ;
MILLS, R ;
ALEXANDER, S ;
TORREZMARTINEZ, N ;
JAHNKE, R ;
ROSS, G .
LANCET, 1992, 339 (8794) :645-646